design and optimization of linear and cyclic peptides against challenging targets, including “undruggable” protein-protein interactions.

Small molecule Platform: De novo AI-driven design of small molecules by leveraging key interactions related to biological activity with multiparametric optimization of over 80 drug properties.

Induced Proximity Platform Engineering ternary complexes to transform structurally unresolved native and induced PPIs into druggable targets.

Multilevel AI-driven Drug Discovery Infrastructure: Our drug discovery infrastructure consists of four hierarchical levels that facilitate seamless AI-driven preclinical drug discovery pipeline. Advanced data acquisition, generation and augmentation backs up state-of-the-art predictive and generative AI models for all major drug discovery tasks. These models empower dedicated workflows for different drug modalities and target classes. The whole discovery process is supervised and orchestrated by LLM agents that blend together human expertise and artificial intelligence.